Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Stelara
Ustekinumab is a human monoclonal antibody that targets the p40 subunit common to interleukin (IL)-12 and IL-23, cytokines that play a key role in inflammatory and immune responses. It is used to treat various inflammatory conditions, including plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. By blocking these cytokines, ustekinumab inhibits the activation and proliferation of certain immune cells involved in the inflammatory cascade.
Ustekinumab is used to treat moderate to severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis.
Patients treated with ustekinumab are at increased risk of serious infections, including tuberculosis and invasive fungal infections. Malignancies, including lymphoma and non-melanoma skin cancer, have also been reported. Patients should be evaluated for latent tuberculosis infection before initiating therapy.
Outcome:
Increased risk of infection
Mechanism:
Ustekinumab suppresses the immune system
Outcome:
Reduced efficacy of ustekinumab
Mechanism:
Unknown
Outcome:
No clinically significant interaction
Mechanism:
None known
Most likely new formulation: Subcutaneous auto-injector pen (2025, 80% confidence)
Based on current usage trends and ongoing clinical trials, there is a 70% likelihood of expanded indications for ustekinumab in other inflammatory conditions within the next 5 years.
Immunosuppressant, Interleukin-12/23 inhibitor
Monoclonal Antibody